{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:22:53Z","timestamp":1791285773549,"version":"4.1.0"},"reference-count":11,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2001,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Human granulocytic ehrlichiosis is a recently described disease caused by an obligate intracellular gram-negative organism recently named\n            <jats:italic>Ehrlichia phagocytophila<\/jats:italic>\n            . To expand our knowledge of the susceptibility of\n            <jats:italic>E. phagocytophila<\/jats:italic>\n            , we tested six New York State isolates for susceptibility to 12 antimicrobials using an HL-60 cell culture system. All of the isolates were susceptible to doxycycline (MIC, \u22640.125 \u03bcg\/ml; minimum bactericidal concentration [MBC], 0.125 to 0.5 \u03bcg\/ml), rifampin (MIC, \u22640.125 \u03bcg\/ml; MBC, \u22640.125 \u03bcg\/ml), ofloxacin (MIC, \u22642 \u03bcg\/ml; MBC, \u22642 \u03bcg\/ml), levofloxacin (MIC, \u22641 \u03bcg\/ml; MBC, \u22641 \u03bcg\/ml), and trovafloxacin (MIC, \u22640.032 \u03bcg\/ml; MBC, \u22640.032 \u03bcg\/ml). Isolates were uniformly resistant to amoxicillin, ceftriaxone, erythromycin, azithromycin, clarithromycin, and amikacin. For one strain, the MBC of chloramphenicol was \u22648 \u03bcg\/ml. These data suggest that quinolone antibiotics and rifampin may be alternative agents for patients with intolerance to tetracyclines.\n          <\/jats:p>","DOI":"10.1128\/aac.45.3.786-788.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"786-788","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":55,"title":["Antimicrobial Susceptibility of\n            <i>Ehrlichia phagocytophila<\/i>"],"prefix":"10.1128","volume":"45","author":[{"given":"Harold W.","family":"Horowitz","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases and Departments of Medicine,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.-C.","family":"Hsieh","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Biochemistry and Molecular Biology,2 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Aguero-Rosenfeld","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Pathology,3 New York Medical College, Valhalla, New York 10595"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Kalantarpour","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases and Departments of Medicine,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishraq","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases and Departments of Medicine,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P.","family":"Wormser","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases and Departments of Medicine,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Wu","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Biochemistry and Molecular Biology,2 and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-11-199612010-00006"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03520030054028"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1086\/515048","article-title":"Seroprevalence of human granulocytic ehrlichiosis among permanent residents of northwestern Wisconsin.","volume":"27","author":"Bakken J. S.","year":"1998","unstructured":"Bakken J. S. Goellner P. Van Etten M. Boyle D. Z. Swonger O. L. Mattson S. Freuth J. Tilden R. L. Asanovich K. Walls J. Dumler J. S. Seroprevalence of human granulocytic ehrlichiosis among permanent residents of northwestern Wisconsin. Clin. Infect. Dis. 27 1998 1491 1496","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1086\/517678","article-title":"Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin.","volume":"27","author":"Buitrago M. I.","year":"1998","unstructured":"Buitrago M. I. IJdo J. W. Rinaudo P. Simon H. Copel J. Gadbaw J. Heimer R. Fikrig E. Bia F. J. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin. Infect. Dis. 27 1998 213 215","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601253340401"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.1.76"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1086\/514683","article-title":"Human granulocytic ehrlichiosis in Europe: clinical and laboratory findings for four patients from Slovenia.","volume":"27","author":"Lotric-Furlan S.","year":"1998","unstructured":"Lotric-Furlan S. Petrovec M. Zupanc T. A. Nicholson W. L. Sumner J. W. Childs J. E. Strle F. Human granulocytic ehrlichiosis in Europe: clinical and laboratory findings for four patients from Slovenia. Clin. Infect. Dis. 27 1998 424 428","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707033370105"},{"key":"e_1_3_2_10_2","unstructured":"National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard fifth edition. Document M7\u2013A5. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.12.6209"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904153401517"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.3.786-788.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.3.786-788.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:09:34Z","timestamp":1645463374000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.45.3.786-788.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["10.1128\/AAC.45.3.786-788.2001"],"URL":"https:\/\/doi.org\/10.1128\/aac.45.3.786-788.2001","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]},"assertion":[{"value":"2000-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-12-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}